Literature DB >> 2847328

Intrathoracic granular cell myoblastoma.

J M Robinson1, R Knoll, D A Henry.   

Abstract

Intrathoracic granular cell myoblastoma (GCM) is most commonly a benign neoplasm of Schwann cell origin that occurs in the large airways, the segmental bronchi, and rarely in the mediastinum. The tumor predominantly affects blacks during the fourth decade, and shows no sex predilection. Tracheobronchial GCM most commonly produces cough and chest pain, with focal consolidation or atelectasis shown on chest x-ray films. Extraesophageal mediastinal GCM produces few or no symptoms, and should be included in the differential diagnosis of a posterior mediastinal mass. Computerized tomography is helpful in evaluating the extent of the lesion, defining its relationship to adjacent structures, and planning the therapeutic approach. The diagnosis of tracheobronchial GCM usually can be made by bronchoscopy and/or biopsy. Treatment remains controversial, but most studies suggest surgical or endoscopic resection as the treatment of choice. The prognosis of intrathoracic GCM is good but is dependent upon complete removal.

Entities:  

Mesh:

Year:  1988        PMID: 2847328     DOI: 10.1097/00007611-198811000-00030

Source DB:  PubMed          Journal:  South Med J        ISSN: 0038-4348            Impact factor:   0.954


  3 in total

Review 1.  Solitary, multiple, benign, atypical, or malignant: the "Granular Cell Tumor" puzzle.

Authors:  Isidro Machado; Julia Cruz; Javier Lavernia; Antonio Llombart-Bosch
Journal:  Virchows Arch       Date:  2015-12-05       Impact factor: 4.064

2.  Preoperative diagnosis of a mediastinal granular cell tumor by EUS-FNA: a case report and review of the literature.

Authors:  Sarah M Bean; Mohamad A Eloubeidi; Isam A Eltoum; Robert J Cerfolio; Darshana N Jhala
Journal:  Cytojournal       Date:  2005-06-08       Impact factor: 2.091

Review 3.  Mesenchymal tumours of the mediastinum--part II.

Authors:  Michael A den Bakker; Alexander Marx; Kiyoshi Mukai; Philipp Ströbel
Journal:  Virchows Arch       Date:  2015-09-10       Impact factor: 4.064

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.